Simvastatin and Fenofibrate

Therapeutic indications

Simvastatin and Fenofibrate is indicated for:

High cardiovascular risk adult patients with mixed dyslipidaemia

Population group: only adults (18 years old or older)

Fenofibrate/simvastatin combination is indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adult patients with mixed dyslipidaemia to reduce triglycerides and increase HDL-C levels when LDL-C levels are adequately controlled with the corresponding dose of simvastatin monotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Simvastatin and Fenofibrate is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Moderate renal impairment, severe renal impairment

at least one of



Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Liver disease, persistent elevations of serum transaminases

at least one of
Elevated liver enzymes level
Hepatic insufficiency

Concomitant administration of glecaprevir/pibrentasvir

at least one of
Glecaprevir and pibrentasvir
Glecaprevir and additionally Pibrentasvir

History of myopathy and/or rhabdomyolysis with statins and/or fibrates

at least one of
Disorder of muscle
H/O: musculoskeletal disease

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: CHOLIB Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈